Karyopharm Therapeutics Inc.
KPTIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeKaryopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company carries a $11.7M market cap, placing it firmly in the micro-cap category. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Market Cap
$11.7M
Beta
1.04
P/E (TTM)
—
P/E (Fwd)
-0.18
EPS (TTM)
$-18.44
EPS (Fwd)
$-2.82
ROE
—
ROA
-47.6%
Cash
$65.1M
Total Debt
$328.5M
Free CF
-$29.7M
52W Change
-91.8%
Annual Financials
Cash vs Debt
Where KPTI stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, KPTI finished 94.02% below its 150-day moving average ($5.85) and 94.50% below its 200-day moving average ($6.36). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KPTI overbought or oversold?
At the October 20, 2026 close, KPTI's RSI(14) was 9.1, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, KPTI has $65.1M in cash with $328.5M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$29.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has been relatively flat, moving from $157.1M (2022) to $146.1M (2025).
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Karyopharm Therapeutics Inc.'s trajectory.